Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease

Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease

In type 2 diabetes, anti-thrombotic management is challenging, and current anti-platelet agents have demonstrated reduced efficacy. Old and new anti-diabetic drugs exhibited—besides lowering blood glucose levels—direct and indirect effects on platelet function and on thrombotic milieu, eventually co...

Full description

Bibliographic Details
Main Authors: Annunziata Nusca, Dario Tuccinardi, Silvia Pieralice, Sara Giannone, Myriam Carpenito, Lavinia Monte, Mikiko Watanabe, Ilaria Cavallari, Ernesto Maddaloni, Gian Paolo Ussia, Silvia Manfrini, Francesco Grigioni
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Pharmacology
Subjects:
anti-diabetic therapies
glucose-lowering drugs
platelet
anti-platelet agents
cardiovascular disease
thrombotic risk
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.670155/full
id doaj-c49eac255308402dbfd1b88e46db6d74
record_format Article
spelling doaj-c49eac255308402dbfd1b88e46db6d742021-05-12T06:37:31ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-05-011210.3389/fphar.2021.670155670155Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular DiseaseAnnunziata Nusca0Dario Tuccinardi1Silvia Pieralice2Sara Giannone3Myriam Carpenito4Lavinia Monte5Mikiko Watanabe6Ilaria Cavallari7Ernesto Maddaloni8Gian Paolo Ussia9Silvia Manfrini10Francesco Grigioni11Unit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Rome, ItalyUnit of Endocrinology and Diabetes, Department of Medicine, Campus Bio-Medico University of Rome, Rome, ItalyUnit of Endocrinology and Diabetes, Department of Medicine, Campus Bio-Medico University of Rome, Rome, ItalyUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Rome, ItalyUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Rome, ItalyUnit of Endocrinology and Diabetes, Department of Medicine, Campus Bio-Medico University of Rome, Rome, ItalyDepartment of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, Rome, ItalyUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Rome, ItalyDepartment of Experimental Medicine, Sapienza University of Rome, Rome, ItalyUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Rome, ItalyUnit of Endocrinology and Diabetes, Department of Medicine, Campus Bio-Medico University of Rome, Rome, ItalyUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Rome, ItalyIn type 2 diabetes, anti-thrombotic management is challenging, and current anti-platelet agents have demonstrated reduced efficacy. Old and new anti-diabetic drugs exhibited—besides lowering blood glucose levels—direct and indirect effects on platelet function and on thrombotic milieu, eventually conditioning cardiovascular outcomes. The present review summarizes existing evidence on the effects of glucose-lowering agents on platelet properties, addressing pre-clinical and clinical research, as well as drug–drug interactions with anti-platelet agents. We aimed at expanding clinicians’ understanding by highlighting new opportunities for an optimal management of patients with diabetes and cardiovascular disease. We suggest how an improvement of the thrombotic risk in this large population of patients may be achieved by a careful and tailored combination of anti-diabetic and anti-platelet therapies.https://www.frontiersin.org/articles/10.3389/fphar.2021.670155/fullanti-diabetic therapiesglucose-lowering drugsplateletanti-platelet agentscardiovascular diseasethrombotic risk
collection DOAJ
language English
format Article
sources DOAJ
author Annunziata Nusca
Dario Tuccinardi
Silvia Pieralice
Sara Giannone
Myriam Carpenito
Lavinia Monte
Mikiko Watanabe
Ilaria Cavallari
Ernesto Maddaloni
Gian Paolo Ussia
Silvia Manfrini
Francesco Grigioni
spellingShingle Annunziata Nusca
Dario Tuccinardi
Silvia Pieralice
Sara Giannone
Myriam Carpenito
Lavinia Monte
Mikiko Watanabe
Ilaria Cavallari
Ernesto Maddaloni
Gian Paolo Ussia
Silvia Manfrini
Francesco Grigioni
Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease
Frontiers in Pharmacology
anti-diabetic therapies
glucose-lowering drugs
platelet
anti-platelet agents
cardiovascular disease
thrombotic risk
author_facet Annunziata Nusca
Dario Tuccinardi
Silvia Pieralice
Sara Giannone
Myriam Carpenito
Lavinia Monte
Mikiko Watanabe
Ilaria Cavallari
Ernesto Maddaloni
Gian Paolo Ussia
Silvia Manfrini
Francesco Grigioni
author_sort Annunziata Nusca
title Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease
title_short Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease
title_full Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease
title_fullStr Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease
title_full_unstemmed Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease
title_sort platelet effects of anti-diabetic therapies: new perspectives in the management of patients with diabetes and cardiovascular disease
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2021-05-01
description In type 2 diabetes, anti-thrombotic management is challenging, and current anti-platelet agents have demonstrated reduced efficacy. Old and new anti-diabetic drugs exhibited—besides lowering blood glucose levels—direct and indirect effects on platelet function and on thrombotic milieu, eventually conditioning cardiovascular outcomes. The present review summarizes existing evidence on the effects of glucose-lowering agents on platelet properties, addressing pre-clinical and clinical research, as well as drug–drug interactions with anti-platelet agents. We aimed at expanding clinicians’ understanding by highlighting new opportunities for an optimal management of patients with diabetes and cardiovascular disease. We suggest how an improvement of the thrombotic risk in this large population of patients may be achieved by a careful and tailored combination of anti-diabetic and anti-platelet therapies.
topic anti-diabetic therapies
glucose-lowering drugs
platelet
anti-platelet agents
cardiovascular disease
thrombotic risk
url https://www.frontiersin.org/articles/10.3389/fphar.2021.670155/full
work_keys_str_mv AT annunziatanusca plateleteffectsofantidiabetictherapiesnewperspectivesinthemanagementofpatientswithdiabetesandcardiovasculardisease
AT dariotuccinardi plateleteffectsofantidiabetictherapiesnewperspectivesinthemanagementofpatientswithdiabetesandcardiovasculardisease
AT silviapieralice plateleteffectsofantidiabetictherapiesnewperspectivesinthemanagementofpatientswithdiabetesandcardiovasculardisease
AT saragiannone plateleteffectsofantidiabetictherapiesnewperspectivesinthemanagementofpatientswithdiabetesandcardiovasculardisease
AT myriamcarpenito plateleteffectsofantidiabetictherapiesnewperspectivesinthemanagementofpatientswithdiabetesandcardiovasculardisease
AT laviniamonte plateleteffectsofantidiabetictherapiesnewperspectivesinthemanagementofpatientswithdiabetesandcardiovasculardisease
AT mikikowatanabe plateleteffectsofantidiabetictherapiesnewperspectivesinthemanagementofpatientswithdiabetesandcardiovasculardisease
AT ilariacavallari plateleteffectsofantidiabetictherapiesnewperspectivesinthemanagementofpatientswithdiabetesandcardiovasculardisease
AT ernestomaddaloni plateleteffectsofantidiabetictherapiesnewperspectivesinthemanagementofpatientswithdiabetesandcardiovasculardisease
AT gianpaoloussia plateleteffectsofantidiabetictherapiesnewperspectivesinthemanagementofpatientswithdiabetesandcardiovasculardisease
AT silviamanfrini plateleteffectsofantidiabetictherapiesnewperspectivesinthemanagementofpatientswithdiabetesandcardiovasculardisease
AT francescogrigioni plateleteffectsofantidiabetictherapiesnewperspectivesinthemanagementofpatientswithdiabetesandcardiovasculardisease
_version_ 1721443319828971520

Similar Items